Leerink Swann upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from an underperform rating to a market perform rating in a research report report published on Monday. Leerink Swann currently has $50.00 target price on the stock.
Other research analysts also recently issued research reports about the stock. SunTrust Banks Inc. raised shares of Sarepta Therapeutics from a reduce rating to a neutral rating in a research note on Wednesday, September 14th. Jefferies Group reaffirmed an underperform rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. JMP Securities reaffirmed an underperform rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. Janney Montgomery Scott raised shares of Sarepta Therapeutics from a neutral rating to a buy rating and upped their price objective for the company from $30.00 to $65.00 in a research note on Monday. Finally, William Blair raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $88.00 price objective for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $48.70.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The firm’s market cap is $2.92 billion. The company has a 50-day moving average of $30.01 and a 200 day moving average of $21.91. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $61.60.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business earned ($0.87) EPS. On average, equities research analysts expect that Sarepta Therapeutics will post ($4.17) EPS for the current fiscal year.
In other Sarepta Therapeutics news, VP Jayant Aphale sold 35,000 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the sale, the vice president now directly owns 21,490 shares of the company’s stock, valued at $1,074,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David T. Howton sold 9,304 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $465,200.00. Following the completion of the sale, the senior vice president now directly owns 11,168 shares in the company, valued at $558,400. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
A number of large investors have recently modified their holdings of the company. State Street Corp raised its stake in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at $13,506,000. A.R.T. Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at $7,461,000. Eagle Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at $4,712,000. 72.09% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.